|
Published by: Best Practices, LLC
Published: Mar. 1, 2009 - 108 Pages
Table of Contents
- EXECUTIVE SUMMARY
- Introduction
- Research Approach
- Participating Companies
- Table 1.1: Participating Companies
- Figure 1.1: Participant Job Titles
- Figure 1.2: Benchmark Partners’ Experience
- Definitions and Abbreviations
- Report Structure and Organization
- Key Findings
- USING PUBLIC RELATIONS TOOLS FOR OPTIMAL ADVANTAGE
- Figure 2.1: Apply Public Relations Tools and Tactics throughout the Lifecycle
- Figure 2.2: Public Relations Tool Effectiveness Changes Over the Brand Lifecycle
- Figure 2.3: Media Interviews Get Company’s Message Out Best
- Figure 2.4: Blogs and Social Networks Get Message Out in New Ways
- Figure 2.5: Patient Groups, Human-Interest Key to Informing Patients and Family
- Figure 2.6: Public Relations Positioning Tactics Offer Brand Teams Many Options
- Figure 2.7: Human-Interest Stories Resonate with Patients, Media
- Figure 2.8: Tactical Elements Appealing to Consumers Rated Best Public Relations Calls-to-Action
- Figure 2.9: Ask Physician about Condition Rates Highest
- Figure 2.10: Public Relations Calls-to-Action Direct Consumers to Experts & Expertise
- Figure 2.11: Inform and Inspire Consumers to Take Action on Their Own Behalf
- Figure 2.12: Web-based Calls-to-action Direct Patients to Resources
- Figure 2.13: Medical Condition Websites are Most Highly Rated
- Figure 2.14: Brand Websites Have More Options to Engage Consumers Resources and Support Services
- Figure 2.15: Consumers Relate Well to Patient Stories
- Figure 2.16: Best Web-Based Resources Inform and Engage Patients
- Figure 2.17: Testimonials Offer Valuable Hope and Tips for Patients
- Figure 2.18: Patient Advocacy Groups Are Key Partners
- Figure 2.19: Key Public Relations Support Resources Help Inform Patients
- Figure 2.20: Trusted Information Sources are Best Support Service Effectiveness, Timing and Budget
- Figure 2.21: Pre-Launch, Launch & Growth Phases Benefit Greatly From Public Relations
- Figure 2.22: Public Relations Budgets as Percent of Annual Marketing Spend
- Figure 2.23: Measuring Public Relations is a Double-Edged Sword
- Figure 2.24: Public Relations Performance Metrics Are Critical but Imprecise
- Figure 2.25: Begin Public Relations early to bridge From One Brand To Successor
- PRE-LAUNCH
- Figure 3.1: Public Relations Can Create Buzz for New Treatment Paradigms
- Figure 3.2: Formula for Bringing Non-Intuitive Mechanism of Action Medicines To Market
- Figure 3.3: Public Relations Tool Effectiveness at Pre-Launch
- Figure 3.4: Employ Public Relations to Reach Consumers through Patient Advocacy Groups
- Figure 3.5: Early Public Relations Guides Consumers to Trusted Third-Party Info Resources
- Figure 3.6: Introduce New Medical Ideas through Third-Party Expertise: Cymbalta
- Figure 3.7: Inform Consumers through PR, Educational Messages & Personal Stories: Cymbalta
- Figure 3.8: Shaping the Market for Successful Entry of New Products: Rituxan
- Figure 3.9: Early Advisory Board Harvests Insights & Seeds New Ideas
- Figure 3.10: Dare to Kick-Start Debate Before Full Clinical Data are Available
- Figure 3.11: Incite Scientific Discussion - But Don’t Promote Off-Label
- Figure 3.12: Pre-Launch Scientific Communications
- Figure 3.13: B-Cell Dinners: Use Peer-to-Peer Discussions to Extend Science
- Figure 3.14: Seminars and Congresses Extend Message to Broader Audience
- Figure 3.15: Carefully Manage Expectations Pre-Launch
- Figure 3.16: Carefully Manage Expectations Post-Launch
- Figure 3.17: Blue Print for Market-Entry Success
- LAUNCH
- Figure 4.1: Using Experts, Media and Ed Events to Educate at Launch
- Figure 4.2: Build Positive Coverage by Providing Media Access to KOLs
- Figure 4.3: Media Spotlights Can Reach Millions in a Few Seconds
- Figure 4.4: Human-Interest Positioning Touches Hearts
- Figure 4.5: Patient Advocacy Groups Are Trusted Sources of Information
- Figure 4.6: Differentiating a Product Means Building Advocacy Group Bridges
- Figure 4.7: High-Impact Public Relations Campaigns Relate the Medical Condition To the Consumer
- Figure 4.8: Relate the Medical Condition to the Consumer
- Figure 4.9: Employ Public Relations Tools to Help Patients Assess Their Personal Risk
-
- Case Study Spotlight: Slentrol
- Figure 4.10: Pfizer Focuses Its Marketing Skills on Animal Health
- Figure 4.11: Engage Consumers in Disease Awareness Research
- Figure 4.12: Later Public Relations Drives Consumers to Branded Website
- Figure 4.13: BARC as a Diagnostic Tool
- Figure 3.14: New Media Public Relations Were Integral to Slentrol’s
- Campaign
- BRAND-BUILDING
- Figure 5.1: Public Relations Tools, Post-Launch
- Figure 5.2: Websites with Referral Mechanisms Expand Reach
- Figure 5.3: Public Relations Success Stories Often Involve Partnerships
- Figure 5.4: Employ Public Relations Lifestyle Campaigns to Educate and
- Personalize the Condition
- Figure 5.5: Edgy Public Relations Raises Awareness for Symptomless Conditions
- Case Study Spotlight: Flomax
- Figure 5.6: Anchor Brand Positioning Public Relations in Science, Safety, and Unmet Need
- Figure 5.7: A Celebrity Spokesperson Can Help Personalize and Educate
- Figure 5.8: Flomax Branded Website around the One-Week Challenge
- Figure 5.9: Websites Are an Essential Tool in Patient and Family Education
- Figure 5.10: Motivate Men to Seek “One Week” Improvement in Quality Of Life
- Figure 5.11: Target Patient’s Family to Accelerate Treatment Pathway
- LATE-LIFE MANAGEMENT
- Figure 6.1: Later Stage Public Relations Tool Effectiveness
- Figure 6.2: Position Product Public Relations to Reflect Total Cost Benefits
- Figure 6.3: Public Relations Leveraging: Flomax
- Case Study Spotlight: Nexium
- Figure 6.4: Build Bridges between Product Generation to Transition Patients
- Figure 6.5: Provide Info Support throughout the Customer Lifecycle
- Figure 6.6: Employ Tools to Seed and Grow Relationships with Patients in Chronic Care Conditions
- Figure 6.7: Education Tools Inform and Help Patients Self-Diagnose
- Figure 6.8: Polls Educate, Inform & Engage Patients
- Figure 6.9: Engage Patients on Lifestyle Fronts
- Figure 6.10: Employ Technologies to Extend Education to Patient Populations
- Figure 6.11: Public Relations Campaigns Trumpet “Nexium-Kids” Version
- Figure 6.12: A Celebrity Spokesperson Helps to Humanize Medical Conditions
- PATENT EXPIRATION MANAGEMENT
- Figure 7.1: Effective Public Relations Tools, Patent Expiration
- Case Study Spotlight: Fluvirin
- Figure 7.2: Use YouTube to Create Buzz and Flu Awareness
- Figure 7.3: Use a Contest to Engage Amateurs and Professionals
- LESSONS LEARNED
- General Good Practices
- Figure 8.1: Public Relations Tools Help Educate and Inform the Market
- Engage, Inform and Educate
- Tailor Late-Stage Tactics to Reach Select Sub-Populations
- Bridge the Gap between Product Generations
AbstractSavvier consumers and competition from generic drugs have made commercial success, whether at market entry or during brand maturity, more elusive. At the same time, new technologies have greatly expanded the ability of cost-efficient Public Relations to support pharmaceutical brand growth.
Thus, while industry trends introduce challenges to product commercialization, technology is enabling PR leaders to fashion innovative PR campaigns. New media channels like the Internet have improved the reach of Public Relations through such forums as online disease state awareness groups and brand websites. The immediacy of these media has also enhanced the opportunity for shrewdly timing and executing PR activities in the product lifecycle.
This Best Practices, LLC benchmarking report identifies the most current and effective PR tools and calls-to-action, and explores how top companies align these tactics with each stage of a product’s lifecycle. Pharmaceutical executives and directors can use this research to optimize Public Relations during launch and brand-building years, and implement a PR strategy that can help build a bridge from first to next-generation product success.
This research also features four case studies detailing Public Relations success stories, all at different lifecycle stages: Slentrol (Product Launch), Flomax (Brand-Building), Nexium (Product Maturity) and Fluvirin (Patent Expiration).
INDUSTRIES PROFILED:
Health Care; Pharmaceutical; Biotechnology; Chemical
COMPANIES PROFILED:
Abbott; AstraZeneca; AtheroGenics; Boehringer Ingelheim; Boiron; Cubist Pharmaceuticals; Emcure; Farmasa Schwabe; Gebauer Company; Jazz Pharmaceuticals; Johnson & Johnson; Merck Serono; Novartis; Novo Nordisk; Pfizer; Solvay; Wyeth
STUDY SNAPSHOT
Marketing and Public Relations executives, directors and managers at 18 pharmaceutical companies participated in an in-depth online survey, and six executives, via deep-dive interviews, contributed their insights to this report. This research yields extensive benchmarking data on and best practices for achieving Public Relations excellence throughout the entire life of a product. Core topics covered include:
- Using Public Relations Tools for Optimal Advantage
- Public Relations during Pre-Launch
- Public Relations during Launch
- Public Relations during Brand-Building
- The Role of Public Relations in Late-Life Management
- Public Relations and Patent Expiration Management
- Ideal Budget Ratios and Performance Measurements
- Lesson Learned and General Good Practices
Four case studies are featured, detailing Public Relations success stories at different lifecycle stages: Slentrol (Product Launch), Flomax (Brand-Building), Nexium (Product Maturity) and Fluvirin (Patent Expiration).
KEY FINDINGS
Among the findings that emerged from this research were the following:
Public Relations in Launch & Brand-Building: The lifecycle phases where PR tactics appeared to be the most effective and actively used were at launch and the brand-building years. Websites are key tools for reaching patients, family members and physicians during these phases. Nearly two-thirds of all research participants positively assessed the following PR tools during launch and brand building years: use of the media, appeals to trusted experts, conducting educational events, producing educational materials and advertorials and sponsoring patient advocacy groups.
PR Relevance to Patients & Consumers: Field research revealed a “holy trinity” for PR specialists. The three aspects of this operational strategy are human-interest positioning, lifestyle positioning and family relevance positioning. Public Relations campaigns that touch these groups tend to engage consumers and win media attention.
Building Bridges: Integrated Public Relations and communication strategies helped AstraZeneca and Eli Lilly build sturdy bridges from Prilosec to Nexium and from Prozan to Cymbalta. This “bridge building” requires good planning and, ideally, should commence at the back end of the first-generation product’s lifecycle.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2009
|